【www.zhangdahai.com--毕业论文】
[摘要] 目的：探讨胸腺素Tα1治疗伴有肝损害的肾综合征出血热的临床疗效。方法：回顾性分析本院2009年8月～2010年12月住院确诊为肾综合征出血热患者共86例，将上述病例按入院先后分为两组，治疗组54例，对照组32例，两组患者入院后的基础治疗和综合治疗相同，但治疗组同时加服胸腺素Tα1 1.6 mg，隔日1次，皮下注射，连用14 d。观察两组的临床疗效。结果：肝功能正常时间治疗组平均为（12.50±2.25） d，对照组平均为（18.20±3.28） d，两组差异有统计学意义（P＜0.05）。疼痛消失t=13.59，P＜0.01；体温正常t=9.48，P＜0.01；尿蛋白消失t=6.75，P＜0.05；血小板复常t=2.86，P＜0.05；BUN复常t=6.86，P＜0.01；住院天数t=6.31，P＜0.01。未发现胸腺素Tα1存在任何副作用。结论：胸腺素Tα1治疗伴有肝损害的肾综合征出血热效果显著，可以提高和调节细胞免疫功能。
[关键词] 胸腺肽；肝损害；肾综合征出血热；临床观察
[中图分类号] R6 [文献标识码] A [文章编号] 1674-4721（2012）01（b）-050-02
Thymosin Tα1 treatment of liver injury associated with hemorrhagic fever with renal syndrome observed 86 cases
LIU Yingquan
Jinzhou City Hospital for Infectious Diseases, Liaoning Province, Jinzhou 120017, China
[Abstract] Objective: To investigate the treatment of thymosin Tα1 liver damage associated with hemorrhagic fever with renal syndrome clinical efficacy. Methods: A retrospective analysis of our hospital from August 2009 to December 2010 diagnosed hospitalized patients with hemorrhagic fever with renal syndrome in 86 cases, the above cases had divided into two groups according to admission, treatment group 54 patients and the control group of 32 patients, two groups of patients admitted to hospital after basic treatment and comprehensive treatment of the same, but the treatment group were given additional thymosin Tα1 1.6 mg, every other day, subcutaneous injection, once every 14 d. Clinical efficacy were observed. Results: Liver function normal time, the treatment group on average (12.50±2.25) d, an average of the control group (18.20±3.28) d, there was significant difference (P
